Orchid Pharma faces liquidation as lenders reject resolution plan

MUMBAI: The lenders to Orchid Pharma have rejected the resolution plan of the bankrupt company, a decision that could push the troubled drug-maker toward liquidation. “The resolution professional has conducted three rounds of bidding.

However, lenders found bids in all the rounds unacceptable,” two senior persons who did not want to be named told ET late Monday. Time was running out for resolving this outstanding debt: The 270- day deadline before which a resolution has to be in place ended on May 14.

Orchid Pharma was referred to the bankruptcy court by Lakshmi Vilas Bank after it failed to pay about Rs 3,500 crore to lenders. It is also in the second list of 28 companies that the Reserve Bank of India had mandated banks to refer to the bankruptcy court by the end of December 2017 if lenders were unable restructure the respective loans by mid-December.

In the third round, the RP received four applications, of which three were legally compliant. At an e-voting held on May 12, the majority of the lenders rejected the offers they received and no resolution plan was put in place by May 14 – the last day of submitting a plan to the bankruptcy court. It is yet not clear whether the RP will seek additional time from the bankruptcy court to revive the company with a resolution plan.

Orchid Pharma has informed the stock exchange that as “the proposed resolution plan that was put for voting did not get requisite approval from the Committee of creditors (CoC), the CoC, through the RP has not submitted a resolution plan with Hon’ble National Company Law Tribunal.”

Union Quimico Farmacéutica, Ingen Capital and Fidelity Trading Corporation were the three bidders in the second round of auctions held in April but their bids were rejected since two of them – Ingen Capital and Fidelity Trading Corporation – were found to be ineligible as they were not compliant with Section 29A of the insolvency code. The offer from Union Quimico Farmacéutica was too low even though it was eligible.

As per the bankruptcy norms, Section 29A bars those companies that have defaulted on payments to lenders from bidding for other stressed assets.

Earlier in April, a bank official told ET that the bid of Union Quimico Farmacéutica was eligible but lenders found its offer of Rs 600 crore payable over a period of three to six years unacceptable.

  • Related Posts

    • Pharma
    • April 28, 2025
    • 90 views
    Gujrat leads pharma sector with record 183 new plants

    Ahmedabad:  Gujarat has further cemented its position as India’s pharmaceutical powerhouse with the state’s Food and Drug Control Administration (FDCA) approving 183 new allopathic drug manufacturing facilities in FY 2024-25,…

    • Pharma
    • April 28, 2025
    • 98 views
    Doctor not liable for prescribing costly drug: HC

    Cuttack:  Orissa high court has ruled that a doctor should not be held criminally liable for prescribing a particular drug of any pharmaceutical company for treatment of a disease like…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Gujrat leads pharma sector with record 183 new plants

    Gujrat leads pharma sector with record 183 new plants

    Doctor not liable for prescribing costly drug: HC

    Doctor not liable for prescribing costly drug: HC

    878 Tramadol capsules being smuggled in Scorpio seized, three arrested

    878 Tramadol capsules being smuggled in Scorpio seized, three arrested

    Doctor not criminally liable for prescribing costly drug: Orissa High Court

    Doctor not criminally liable for prescribing costly drug: Orissa High Court